Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro has a market cap or net worth of $85.86 million. The enterprise value is $74.07 million.
Alzamend Neuro has 93.02 million shares outstanding. The number of shares has increased by 30.31% in one year.
|Shares Change (YoY)||+30.31%|
|Shares Change (QoQ)||+0.76%|
|Owned by Insiders (%)||48.58%|
|Owned by Institutions (%)||3.64%|
|EV / Earnings||n/a|
|EV / Sales||n/a|
|EV / EBITDA||n/a|
|EV / EBIT||n/a|
|EV / FCF||n/a|
|Debt / Equity||0.00|
|Debt / EBITDA||0.00|
|Debt / FCF||0.00|
Return on equity (ROE) is -92.10%, which is considered low. The company has a ROIC of -8,505.10%.
|Return on Equity (ROE)||-92.10%|
|Return on Assets (ROA)||-83.60%|
|Return on Capital (ROIC)||-8,505.10%|
|Revenue Per Employee||n/a|
|Profits Per Employee||-$3.25M|
|Effective Tax Rate||n/a|
Stock Price Statistics
|Total Price Change||-81.80%|
|50-Day Moving Average||1.04|
|200-Day Moving Average||1.59|
|Average Volume (30 Days)||1,326,103|
Short Selling Information
The latest short interest is 1.60 million, so 1.72% of the outstanding shares have been sold short.
|Short % of Shares Out||1.72%|
|Short % of Float||3.18%|
|Short Ratio (days to cover)||1.10|
|Earnings Per Share (EPS)||-$0.11|
The company has $11.79 million in cash and no debt, giving a net cash position of $11.79 million or $0.13 per share.
|Cash & Cash Equivalents||11.79M|
|Net Cash Per Share||$0.13|
|Book Value Per Share||0.13|
|Operating Cash Flow||-6.31M|
|Free Cash Flow||-6.31M|
|FCF Per Share||n/a|
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
|Dividend Per Share||n/a|
|Dividend Growth (YoY)||n/a|
The average price target for Alzamend Neuro is $11.48, which is 1,143.77% higher than the current price. The consensus rating is "Buy".
|Price Target Difference||1,143.77%|
This stock does not have any record of stock splits.
|Last Split Date||n/a|